Novartis Slumps after Pulling Zelnorm
Swiss pharmaceutical giant Novartis (NVS) said Mar. 30 it's suspended its U.S. marketing and sales of Zelnorm, a treatment for constipation caused by irritable bowel syndrome. The Food and Drug Administration suggested the treatment carries with it a risk of heart problems or strokes.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.